Diane W. Wara, M.D. Safety of Recombinant HIV-1 Envelope Vaccines in Newborns of Infected Mothers - a Phase I Study.
Citation
Lynne M. Mofenson, M.D., F.A.A.P. Pharmacokinetics of P24 Antibody (Ab) in HIV+ Pregnant Women & Newborns Receiving Hyperimmune HIV Immunoglobulin (HIVIG) in ACTG Protocol 185.
Citation
John S. Lambert, M.D. Safety and Pharmacokinetics of Hyperimmune HIV Immunoglobulin (HIVIG) in HIV+ Pregnant Women and Newborns.
Citation
James M. Oleske, M.D., Mary Glenn Fowler, M.D., M.P.H., Michael T. Brady, M.D. AIDS Clinical Trials Group (ACTG) Protocol 219: A PediatricHIV Late Outcomes Protocol.
Citation
Vincent J. Carey, Ph.D. Enhancing the Prognostic Value of Bodily Growth Histories in HIV-Positive Pediatric Cohorts.
Citation
Faith Doyle, R.N.,B.S.N. Perinatal AIDS Clinical trials - Integrating Research Into Primary Care "The Miami Experience".
Citation
Lawrence D'Angelo, M.D., M.P.H. The Enrollment of HIV Infected Adolescents in Clinical Trials: The Experience of ACTG Protocol 220.
Citation
Colleen Clark, M.Ph. Quality of Life Outcomes in Children 6 Months to 4 Years of Age Born of Women Enrolled in a Perinatal HIV Transmission Clinical Trial.
Citation
Donald J. Brambilla, Ph.D. Interkit Differences in Plasma HIV-1 RNA Levels in Mothers Enrolled in WITS/ACTG 076.
Citation
Elizabeth Livingston, M.D., Sheran Patel, D.O., Jashvant D. Unadkat, Ph.D., Ross E. McKinney, Jr., M.D., Arlene D. Bardeguez, M.D., M.P.H., F.A.C.O.G., Mary Jo O'Sullivan, M.D. Placental Transfer of Didanosine (ddI) and Initial Evaluation of Didanosine Toxicity in HIV-1 Infected Pregnant Women and their Offspring.